Evidence map›Paper›PMID 42395404›Full record

ArticlebioRxiv : the preprint server for biology2026

Characterisation of Posterior Predominant Amyloid PET Binding Across Multiple Cohorts.

Joseph Giorgio, Ganna Blazhenets, Susan M Landau, Stefania Pezzoli, Jennifer S Yokoyama, David N Soleimani-Meigooni, Maria C Carrillo, Lea T Grinberg, William W Seeley, Salvatore Spina and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Joseph GiorgioDepartment of Neuroscience, University of California Berkeley, Berkeley, CA, USA.ORCID 0000-0003-3704-5977
Ganna BlazhenetsEdward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Susan M LandauDepartment of Neuroscience, University of California Berkeley, Berkeley, CA, USA.
Stefania PezzoliEdward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Jennifer S YokoyamaEdward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-7274-2634
David N Soleimani-MeigooniEdward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Maria C CarrilloAlzheimer's Association, Chicago, IL, USA.
Lea T GrinbergEdward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
William W SeeleyEdward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Salvatore SpinaEdward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Kelly N NudelmanDepartment of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.
Liana G ApostolovaDepartment of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.
Bradford C DickersonFrontotemporal Disorders Unit and Massachusetts Alzheimer's Disease Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
William J JagustDepartment of Neuroscience, University of California Berkeley, Berkeley, CA, USA.
Gil D RabinoviciEdward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Renaud La JoieEdward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
LEADS Consortium, Alzheimer’s Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Project 2: Biomarker Analysis, Non-Genetic Risk Factors, and Their Genetic InteractionsU19AG079774 · NIA · UNIVERSITY OF PENNSYLVANIA · PI HELENA Chang CHUI, Gyungah Jun · 2023 to 2026
$39.4M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9M
Progressive Aphasia Cognition Anatomy and ProgressionR01NS050915 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI · 2004 to 2026
$11.0M
Tau Metabolism in FTD: From Gene Mutations to Molecular Chaperones and Lysosomal ProteasesU54NS123985 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KARCH, CELESTE MARIE · 2021 to 2025
$9.0M
Early Onset Alzheimer's Disease ConsortiumR56AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2017 to 2017
$7.7M
US-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative ResearchR01AG057234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Claudia Duran-Aniotz, Agustin M. Ibanez · 2019 to 2026
$6.1M
Reimagining Precision Medicine Approaches to AD DiagnosisR35AG072362 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI POSSIN, KATHERINE LAUREL, RABINOVICI, GIL DAN · 2021 to 2025
$4.8M
Elucidating clinical heterogeneity in early-onset AD via genomics, transcriptomics, and neuroimagingR01AG062588 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YOKOYAMA, JENNIFER S · 2019 to 2023
$4.0M
NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS R01 AG057234NIA NIH HHS R01 AG062588NIA NIH HHS R35 AG072362NIA NIH HHS R56 AG057195NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG057195NIA NIH HHS U19 AG079774NINDS NIH HHS R01 NS050915NINDS NIH HHS U54 NS123985
6 · The paper itself

Abstract

The standard approach to quantify amyloid (Aβ) PET averages uptake within a single cortical mask that assumes no clinically relevant spatial heterogeneity in uptake patterns. Here, in a sample of 12,379 clinically impaired participants taken from four phenotypically diverse cohorts we use data-driven approaches to discover heterogeneous patterns of Aβ-PET binding, uncovering a reproducible and clinically relevant pattern of posterior predominant Aβ-PET binding. In particular, Aβ-PET positive participants who have posterior predominant binding are less likely to be

Identifiers

PMID42395404
PMCPMC13320885

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.